Gufic Biosciences Limited
Gufic Biosciences Limited (GUFICBIO) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
gufic.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 215 Cr | 202 Cr | 195 Cr | 203 Cr | 204 Cr | 208 Cr | 205 Cr | 224 Cr | 237 Cr | 231 Cr | 252 Cr | 261 Cr |
| Operating expenses (approx.) | 176 Cr | 165 Cr | 161 Cr | 167 Cr | 166 Cr | 174 Cr | 179 Cr | 190 Cr | 199 Cr | 198 Cr | 205 Cr | 214 Cr |
| EBITDA | 39 Cr | 36 Cr | 34 Cr | 36 Cr | 39 Cr | 34 Cr | 26 Cr | 33 Cr | 38 Cr | 33 Cr | 47 Cr | 47 Cr |
| OPM % | 18.3% | 18.1% | 17.6% | 17.6% | 18.9% | 16.3% | 12.9% | 14.9% | 16.0% | 14.3% | 18.7% | 17.9% |
| Other income | 0.33 Cr | 0.42 Cr | 0.88 Cr | 1 Cr | 0.11 Cr | 2 Cr | 0.39 Cr | 0.93 Cr | 2 Cr | 0.79 Cr | -1 Cr | 0.46 Cr |
| Interest | 4 Cr | 3 Cr | 4 Cr | 5 Cr | 5 Cr | 5 Cr | 8 Cr | 9 Cr | 10 Cr | 8 Cr | 9 Cr | 9 Cr |
| Depreciation | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 5 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr |
| Profit before tax | 31 Cr | 30 Cr | 27 Cr | 28 Cr | 29 Cr | 26 Cr | 11 Cr | 17 Cr | 23 Cr | 18 Cr | 29 Cr | 30 Cr |
| Tax % | 25.0% | 24.7% | 26.1% | 25.8% | 25.6% | 26.5% | 26.7% | 24.3% | 25.6% | 29.9% | 24.4% | 25.7% |
| Net profit | 23 Cr | 22 Cr | 20 Cr | 21 Cr | 22 Cr | 19 Cr | 8 Cr | 13 Cr | 17 Cr | 12 Cr | 22 Cr | 22 Cr |
| EPS (₹) | ₹2.39 | ₹2.23 | ₹2.00 | ₹2.08 | ₹2.17 | ₹1.93 | ₹0.77 | ₹1.30 | ₹1.68 | ₹1.24 | ₹2.18 | ₹2.22 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 807 Cr | 820 Cr | 944 Cr | Sign in for TTM |
| Operating expenses (approx.) | 661 Cr | 685 Cr | 793 Cr | Sign in for TTM |
| EBITDA | 146 Cr | 135 Cr | 151 Cr | Sign in for TTM |
| OPM % | 18.1% | 16.4% | 16.0% | Sign in for TTM |
| Other income | 2 Cr | 4 Cr | 3 Cr | Sign in for TTM |
| Interest | 15 Cr | 23 Cr | 37 Cr | Sign in for TTM |
| Depreciation | 17 Cr | 21 Cr | 31 Cr | Sign in for TTM |
| Profit before tax | 116 Cr | 94 Cr | 87 Cr | Sign in for TTM |
| Tax % | 25.5% | 26.0% | 25.8% | Sign in for TTM |
| Net profit | 86 Cr | 70 Cr | 64 Cr | Sign in for TTM |
| EPS (₹) | ₹8.74 | ₹6.95 | ₹6.40 | Sign in for TTM |
| Dividend payout % | 1.1% | 1.4% | 1.6% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 10 Cr | 10 Cr | 10 Cr |
| Reserves | 523 Cr | 591 Cr | 655 Cr |
| Borrowings | 317 Cr | 310 Cr | 385 Cr |
| Other liabilities | 243 Cr | 258 Cr | 292 Cr |
| Total liabilities | 1,093 Cr | 1,169 Cr | 1,342 Cr |
| Fixed assets (net) | 153 Cr | 500 Cr | 485 Cr |
| CWIP | 307 Cr | 22 Cr | 22 Cr |
| Investments | 2 Cr | 2 Cr | 2 Cr |
| Loans & advances | 0.37 Cr | 0.32 Cr | 0.66 Cr |
| Inventories | 200 Cr | 217 Cr | 324 Cr |
| Trade receivables | 330 Cr | 315 Cr | 297 Cr |
| Cash & bank | 1 Cr | 16 Cr | 62 Cr |
| Other assets | 98 Cr | 99 Cr | 149 Cr |
| Total assets | 1,093 Cr | 1,169 Cr | 1,342 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | -7 Cr | 123 Cr | 45 Cr |
| Cash from investing | -102 Cr | -71 Cr | -31 Cr |
| Cash from financing | 82 Cr | -37 Cr | 32 Cr |
| Net cash flow | -27 Cr | 15 Cr | 46 Cr |
| Free cash flow (OCF − Capex) | -120 Cr | 47 Cr | 14 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 15.4% | 12.9% | 11.7% |
| ROE % | 16.2% | 0.0% | 0.0% |
| Debtor days | 149 | 140 | 115 |
| Inventory days | 214 | 229 | 278 |
| Days payable | 178 | 168 | 170 |
| Cash conversion cycle | 186 | 201 | 222 |
| Debt / equity | 0.60 | 0.52 | 0.58 |
| Current ratio | 1.61 | 1.61 | 1.55 |
| Net debt / EBITDA | 2.17 | 2.19 | 2.13 |
Compare with peers
Loading peers…